

## Biosimilars Education Impact Assessment Questionnaire

### Before Training

#### What do you know about biosimilars?

Q1a. Before this training, had you heard the term “biosimilar/biosimilarity” in the last month?      No      Yes

Q1b. How well do you understand how biosimilar medicines are **developed**?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

Q1c. How well do you understand how biosimilars are **licensed in the UK**?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

Q1d. How well do you understand the concept of **extrapolation** in regards to biosimilars?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

#### Biosimilars in your practice:

Q2a. How would you expect patients to respond **clinically** to biosimilars compared to the reference/original medicine?

Very much differently    Somewhat differently    Somewhat the same    Very much the same    Not Sure

Q2b. How confident would you be in using biosimilars in your patients?

Not at all confident Very confident  
 0    1    2    3    4    5    6    7    8    9    10

Q2c. How easy do you think it will be to introduce biosimilars into your department?

Impossible Straightforward  
 0    1    2    3    4    5    6    7    8    9    10

Q2d. What issues do you expect to arise if biosimilars are introduced into your department?

.....

## Talking about biosimilars:

Have you ever had a discussion about biosimilars with:

Q3a. **Clinical colleagues:**      No      Yes

How confident were you at explaining what a biosimilar is:

Not at all confident Very confident  
0      1      2      3      4      5      6      7      8      9      10

Q3b. **Patients:**      No      Yes

How confident were you at explaining what a biosimilar is:

Not at all confident Very confident  
0      1      2      3      4      5      6      7      8      9      10

## Biosimilar training

Q4a. Have you previously received any training on biosimilars?    No      Yes

Q4b. If yes, was it provided by:

Someone in your Trust      Professional Body      Pharmaceutical Industry      Other

Q4c. When did you have the training? Less than 1 month, 1-3 months ago, 3-6 months ago, more than 6 months

Q4d. How useful was it?

Not at all useful Very useful  
0      1      2      3      4      5      6      7      8      9      10

Q4e. If less than 10, why?

Too brief      Not enough detail      Too detailed      Not relevant to my role      Too biased

Other:.....

## About you

Q5a    Role:    Nurse      Doctor      Pharmacist      Other (please state) \_\_\_\_\_

Q5b    Therapy Area:

Q5c    Year of registration as a healthcare professional:

The Cancer Vanguard is a partnership between  
Greater Manchester Cancer Vanguard Innovation, RM Partners and UCLH Cancer Collaborative  
This resource is a product of the Joint Working Agreement between The Cancer Vanguard and Sandoz

## About the way you learn

Q6a. How do you prefer to learn new information?

Please select 3 in order of preference where 1=first, 2=second and 3=third

Learning format	Rank
Presentation/Lecture	
Online training	
Ward-based teaching	
Self-directed reading/training	
Attending meetings/congresses	
Webinar	
Interactive training session	
Other (please describe)	

Q6b. On average, how much time do you spend in total on role specific learning **each week**? Please circle most appropriate.

Less than 15min      30min   1hr      2hrs      3hrs      4hrs      5hrs      6hrs      1day

Please note that the following pages are to be used after completion of the training to measure success against the baseline measurements in pages 1, 2 and 3.

## Biosimilars Education Impact Assessment Post-Training Questionnaire

### After Training

#### What do you know about biosimilars *now*?

Q7a. How well do you understand how biosimilar medicines are **developed**?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

Q7b. How well do you understand how biosimilars are **licensed in the UK**?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

Q7c. How well do you understand the concept of **extrapolation** in regards to biosimilars?

I know nothing I have extremely good knowledge  
 0    1    2    3    4    5    6    7    8    9    10

#### Biosimilars in your practice:

Q8a. How would you expect patients to respond **clinically** to biosimilars compared to the reference/original medicine?

Very much differently    Somewhat differently    Somewhat the same    Very much the same    Not Sure

Q8b. How confident would you be in using biosimilars in your patients?

Not at all confident Very confident  
 0    1    2    3    4    5    6    7    8    9    10

Q8c. How easy do you think it will be to introduce biosimilars into your practice?

Impossible Straightforward  
 0    1    2    3    4    5    6    7    8    9    10

## Talking about biosimilars:

How confident do you feel now at explaining what a biosimilar is to...

### Q9a. Clinical colleagues:

Not at all confident Very confident

0    1    2    3    4    5    6    7    8    9    10

### Q9b. Patients:

Not at all confident Very confident

0    1    2    3    4    5    6    7    8    9    10

For your role, please list the three biosimilars topics you would like to learn more about?

1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_